Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Genitourinary Cancer

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Prostate Cancer Prostatic Dis

Morgans AK, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, Ghadessi M, Verholen F, Grimm MO

doi: 10.1038/s41391-026-01076-w

Genitourinary Cancer

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide

Prostate

Martínez Osorio CA, Sopeña Sutil R, Vilaseca Cabo A, Linares Espinós E, Ramírez Backhaus M, Gómez Rivas J, Costa Planells M, Martinez Breijo S, Picola Brau N, Domínguez Esteban N, Muñoz Rodríguez J, Sanchís Bonet A, Guijarro Cascales A, Beamud Cortés M, Servian Vives P, de la Morena Gallego JM, Pérez Márquez M, García Sanz M, Ramón Alemán J, Zamora Horcajada Á, Rodríguez Part V, Hassi Roman M, Rodriguez Concha C, Rios González E, de Pablos-Rodríguez P

doi: 10.1002/pros.70040

Genitourinary Cancer

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry

Eur Urol

Karpinski MJ, Hoberück S, Fendler WP, Civan C, Bundschuh RA, Thomas C, Bjartell A, Trägårdh E, Soeterik TFW, Evangelista L, Vondrak A, Rasul S, Forner L, Giorgio AD, Scholtissek H, Miksch J, Holzgreve A, Lanfranchi F, Rahbar K, Hofman MS, Rauscher I, Güven O, Eiber M, Ayati N, Umutlu L, Herrmann K, Hadaschik B, Emmett L

doi: 10.1016/j.eururo.2025.10.013

Genitourinary Cancer

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Eur J Cancer

Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ

doi: 10.1016/j.ejca.2025.116110

Breast Cancer

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Int J Cancer

Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A

doi: 10.1002/ijc.70397

Genitourinary Cancer

Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Eur Urol

Vigneswaran HT, Palsdottir T, Micoli C, Tilki D, Lin D, Cooperberg M, Eggener S, Falagario UG, Möller A, Aly M, Akre O, Wiklund P, Egevad L, Grönberg H, Nordström T, Eklund M

doi: 10.1016/j.eururo.2025.10.001

Genitourinary Cancer

¹⁷⁷Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

J Clin Oncol

Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J

doi: 10.1200/JCO-25-01553

Genitourinary Cancer

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Prostate Cancer Prostatic Dis

Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F

doi: 10.1038/s41391-026-01077-9

CHICAGO 2026

Genitourinary Cancer

Related content

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer

¹⁷⁷Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study